What Is the Role of Bone Marrow Biopsies in AML Treatment?
https://vimeo.com/948960276 What part do bone marrow biopsies play in acute myeloid leukemia (AML) treatment? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses the value and information gained…
Why Is Shared Decision-Making Important for AML Patients?
https://vimeo.com/948960301 What makes shared decision-making vital for acute myeloid leukemia (AML) patients? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses his approach to shared decision-making, the roles…
Do AML Bone Marrow Biopsies Show Racial and Ethnic Variances?
https://vimeo.com/948960333 Are racial and ethnic differences shown in acute myeloid leukemia (AML) bone marrow biopsies? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses what early AML studies…
How Bone Marrow Biopsies Impact Acute Myeloid Leukemia Treatment and Care
https://vimeo.com/948960365 How are acute myeloid leukemia (AML) treatment and care impacted by bone marrow biopsies? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School explains the role that bone…
Novel AML Therapy Use | Impact of Socioeconomic Status and Other Factors
https://vimeo.com/948960382 How do socioeconomic status and other factors impact novel acute myeloid leukemia (AML) therapy use? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses major factors that…
Underrepresented AML Clinical Trial Groups | What Solutions Are Underway?
https://vimeo.com/948960402 What steps are being taken to help underrepresented acute myeloid leukemia (AML) clinical trial groups? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses an important approach…
Why Is Post-Access Enrollment Vital in AML Clinical Trial Participation?
https://vimeo.com/948960428 For acute myeloid leukemia (AML) clinical trial participation, what makes post-access enrollment essential? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that play into post-access…
What AML Clinical Trial Inequities Do Minority and Ethnic Groups Face?
https://vimeo.com/948960457 Do minority and ethnic groups face acute myeloid leukemia (AML) clinical trial inequities? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses research study results of NCI-designated…
What Are Key Acute Myeloid Leukemia Care Barriers and Solutions?
https://vimeo.com/948960484 What are key barriers and solutions to acute myeloid leukemia (AML) care? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that create AML care barriers,…
[ACT]IVATED AML Resource Guide II
Download Resource Guide Download Resource Guide See More from [ACT]IVATED AML Share Your Feedback About [ACT]IVATED AML
[ACT]IVATED AML Resource Guide II en español
Download Resource Guide Download Resource Guide See More from [ACT]IVATED AML Share Your Feedback About [ACT]IVATED AML
Advancing Equity | Research Initiatives in AML Disparities Among Black and Latinx Populations
What AML research efforts are underway to advance equity among Black and Latinx and populations? Expert Dr. Sara Taveras Alam from UTHealth Houston discusses initiatives that are working to improve AML care…